Latest / Ageless and Timeless Podcast® / From Fighter to Founder: Ed Clay’s Mission to Transform the Future of Medicine

Transcript

From Fighter to Founder: Ed Clay’s Mission to Transform the Future of Medicine · Ageless and Timeless Podcast®

• 0:13
  Speaker 1: Hello everyone, This is Michelle Hughes from Ageless and Timeless. Today,
• 0:17
  Speaker 1: I have a guest who actually was the subject of
• 0:20
  Speaker 1: my Top Doctor magazine article if you got to read that.
• 0:25
  Speaker 2: His name is Ed Clay and he is.
• 0:29
  Speaker 1: One of the founders, one of three founders of the
• 0:32
  Speaker 1: tam slash CPI Center in Tijuana. But he has an
• 0:37
  Speaker 1: incredible backstory. So, Ed, welcome to Ageless and Timeless. I'm
• 0:43
  Speaker 1: so happy that you're finally we finally got this connected
• 0:46
  Speaker 1: so we can be together.
• 0:48
  Speaker 3: Yeah, thanks for having me, Michelle.
• 0:50
  Speaker 1: So, Ed, you have one of the most amazing backstories.
• 0:54
  Speaker 1: So let's let's start with just telling us about your journey.
• 0:59
  Speaker 1: How how how did you get to where you are
• 1:01
  Speaker 1: today and what were the key turning points and challenges that.
• 1:07
  Speaker 2: Have brought you here.
• 1:08
  Speaker 4: Yeah.
• 1:09
  Speaker 3: So I was a professional MMA fighter. Gosh, probably it's
• 1:13
  Speaker 3: actually more than twenty years ago now, about twenty five
• 1:15
  Speaker 3: years ago.
• 1:16
  Speaker 4: And I trained professional fighters.
• 1:18
  Speaker 3: Up until I retired in two thousand and eleven, twenty twelve.
• 1:22
  Speaker 3: But you know, my mom was sick without options in
• 1:27
  Speaker 3: the United States. She had rheumatuire arthritis, and she'd failed
• 1:32
  Speaker 3: all the standard of care medications. She broke her back
• 1:36
  Speaker 3: on a short fall due to the side effects. She
• 1:38
  Speaker 3: got multiple staff infections, she got tuberculosis, all due to
• 1:43
  Speaker 3: the side effects of the medications, and so we'd run
• 1:46
  Speaker 3: out of options for her. It was attacking her organs.
• 1:51
  Speaker 3: And so I had read a study on something called
• 1:52
  Speaker 3: Coli'S toxins for rheumatiar arthritis. It was from nineteen twenty three,
• 1:57
  Speaker 3: and Coli'S was not available in the US. Uh, really
• 2:02
  Speaker 3: wasn't available anywhere except one hospital in Mexico that had.
• 2:06
  Speaker 4: Closed about two years before.
• 2:09
  Speaker 3: So my two business partners and I, so Scott Nelson,
• 2:12
  Speaker 3: Detrick Perry, and I got a real estate agent in Tijuana.
• 2:16
  Speaker 3: Uh found the hospital, found the owner, UH, bought the
• 2:21
  Speaker 3: hospital from him, hired back the original staff. Uh My
• 2:26
  Speaker 3: mom was our first patient. She came in a wheelchair,
• 2:28
  Speaker 3: left three weeks later walking in remission and uh yeah,
• 2:32
  Speaker 3: she was in remission for seven and a half years.
• 2:34
  Speaker 3: So that was really the catalyst behind it all. And UH,
• 2:38
  Speaker 3: you know, from from then we've we've grown to you
• 2:40
  Speaker 3: know where we're at today.
• 2:42
  Speaker 2: So ed the how how did they being an m
• 2:46
  Speaker 2: M A fighter.
• 2:50
  Speaker 1: Influence or or condition you to be ready to take
• 2:54
  Speaker 1: on an entrepreneurial mission that is as big as what
• 2:57
  Speaker 1: you're doing today.
• 2:59
  Speaker 3: You know, I think there's a lot of lessons from
• 3:01
  Speaker 3: martial arts and from uh, from fighting, from training fighters, uh,
• 3:07
  Speaker 3: you know, a lot of hard work and discipline, uh,
• 3:11
  Speaker 3: not giving up, perseverance.
• 3:15
  Speaker 4: And really just grit.
• 3:16
  Speaker 3: I think, you know, those things are kind of what
• 3:18
  Speaker 3: it takes to to be successful. And yeah, I had
• 3:23
  Speaker 3: a lot of really great mentors, you know, in my
• 3:26
  Speaker 3: twenties and thirties and h you know, the lessons from
• 3:31
  Speaker 3: my mentors, which were from mostly mixed martial arts, uh,
• 3:35
  Speaker 3: and the aspect of being a fighter myself for a
• 3:39
  Speaker 3: short time and then training professional fighters. All those aspects
• 3:44
  Speaker 3: definitely help you prepare because you know, doing something like
• 3:47
  Speaker 3: this is a it's a lot of mental game, and
• 3:50
  Speaker 3: so you've got to be able to stay really focused
• 3:52
  Speaker 3: and and not give up and not listen to the
• 3:54
  Speaker 3: outside noise, et cetera.
• 3:57
  Speaker 2: And you had a.
• 3:58
  Speaker 1: Father and an uncle, right, who were both fighters before you,
• 4:02
  Speaker 1: so they must have had they were they part of
• 4:05
  Speaker 1: those mentors that you were just referring to.
• 4:08
  Speaker 3: Well, no, no, they weren't part of the mentors. But
• 4:12
  Speaker 3: I mean, my dad and I are very close my
• 4:14
  Speaker 3: dad was a boxer, My uncle was a boxer. I
• 4:17
  Speaker 3: grew up around uh, you know, just watching fights every
• 4:22
  Speaker 3: what Tuesday and Friday night. Uh, we would watch boxing
• 4:26
  Speaker 3: and uh it was a it was a you know,
• 4:29
  Speaker 3: major part of my upbringing.
• 4:31
  Speaker 4: So, yes, I was. I was around it a lot.
• 4:36
  Speaker 1: You know. The thing is that anybody who reads your
• 4:38
  Speaker 1: bio is going to say, well, look, he started out,
• 4:41
  Speaker 1: you know, as a fighter. Then he became a trainer
• 4:44
  Speaker 1: and had one of the largest studios. Then he became
• 4:47
  Speaker 1: a clothing apparel manufacturer with the largest Brazilian jiu jitsu
• 4:53
  Speaker 1: clothing line, and then you know, he morphed because really
• 4:57
  Speaker 1: the influence of your mother, it seems, you know, by
• 5:02
  Speaker 1: a happy accident, you morphed into where you bought the
• 5:06
  Speaker 1: hospital that you now still own. Ten it's been ten
• 5:11
  Speaker 1: years right since you Yeah, so okay, So the hospital,
• 5:16
  Speaker 1: for everybody that's watching, is called TAM TAM slash CPI.
• 5:22
  Speaker 2: So why don't you tell us what those letters mean
• 5:25
  Speaker 2: and how.
• 5:25
  Speaker 1: They came about and go a little deeper than just
• 5:29
  Speaker 1: you know, the actual meaning of I mean, the actual
• 5:32
  Speaker 1: translation of the letters.
• 5:34
  Speaker 4: Yeah.
• 5:34
  Speaker 3: Sure, Well, TAM stands for translational and advanced medical and
• 5:39
  Speaker 3: then we have TAM Center, which is our hospital, six
• 5:43
  Speaker 3: stories about thirty patient rooms, two interventual radiology suites. The
• 5:49
  Speaker 3: sixth floor is where our doctors and scientists work together.
• 5:55
  Speaker 3: Next to them on the sixth floor is the lab
• 5:57
  Speaker 3: where we have one of the most advanced labs really
• 5:59
  Speaker 3: in the world. We have full clinical laboratories genomics, proteomics,
• 6:04
  Speaker 3: digital pathology, flow citometry, and cellular manufacturing, all on the
• 6:09
  Speaker 3: same floor that the doctors and scientists work together. Translational
• 6:13
  Speaker 3: medicine is bench to bedside, so from the bench of
• 6:16
  Speaker 3: the scientists to the bedside of the patient, then back
• 6:19
  Speaker 3: from the bedside of the patient to the bench of
• 6:21
  Speaker 3: the scientists. So it's really translating discoveries and translating patient
• 6:26
  Speaker 3: outcomes and bringing them back to both you know. So TAM,
• 6:31
  Speaker 3: the parent company of everything is called TAM Global. With
• 6:34
  Speaker 3: Under TAM Global we have TAM Center, TAM CPI, TAM Diagnostics,
• 6:41
  Speaker 3: TAM Biosciences, which is our biosciences company where we invent
• 6:45
  Speaker 3: drugs or therapeutics or cellular products and then get those
• 6:50
  Speaker 3: through the clinical trial process, TAM Imaging where we have
• 6:55
  Speaker 3: ct MRI ultrasound tam Data which all of our data
• 7:01
  Speaker 3: goes into, and then tam AI, which is our AI branches,
• 7:05
  Speaker 3: so you know TAM Global. We have the hospital in Mexico,
• 7:09
  Speaker 3: hospitals and labs and imaging in Mexico. We also have
• 7:12
  Speaker 3: a lab in Boston where we do most of our
• 7:15
  Speaker 3: cancer research. We have a lab in Nashville which is
• 7:19
  Speaker 3: TAM Pharmacy. The goal is to be within in forty
• 7:23
  Speaker 3: nine states in the next twelve months, licensed in forty
• 7:25
  Speaker 3: nine states the next twelve months. We also have cellular
• 7:28
  Speaker 3: manufacturing in Nashville, so it's an ecosystem of companies. You know,
• 7:33
  Speaker 3: we're completely vertically integrated to where we can translate findings
• 7:37
  Speaker 3: discoveries fast and get them into patients to where Currently
• 7:41
  Speaker 3: under the FDA model, it takes five to seven years
• 7:44
  Speaker 3: and thirty to fifty million dollars to get a medication
• 7:48
  Speaker 3: to a phase one. Phase one is a phase one safety.
• 7:52
  Speaker 3: We can go from discovery to patient within six to
• 7:54
  Speaker 3: twelve months, so we're not wasting thirty to fifty million dollars,
• 7:57
  Speaker 3: we're not spending five to seven years, and we can
• 8:01
  Speaker 3: if it doesn't work, we move on to something else.
• 8:03
  Speaker 3: If it does work, we run it through the clinical
• 8:06
  Speaker 3: trial process, and so we're really kind of the first
• 8:09
  Speaker 3: of first of it's kind of doing something that is
• 8:12
  Speaker 3: this vertically integrated across the board.
• 8:16
  Speaker 1: Well, and the other thing that people need to know
• 8:18
  Speaker 1: is that the Town Center has really a bifurcated mission.
• 8:24
  Speaker 1: You have one side of the that is cancer focused
• 8:27
  Speaker 1: and the other side is stem cell focus.
• 8:29
  Speaker 2: Of course they do overlap.
• 8:31
  Speaker 1: But why don't you tell us about each of those
• 8:33
  Speaker 1: and how that evolved to where it is today.
• 8:37
  Speaker 3: Yeah, So, you know, CPI stands for Cellular Performance Institute.
• 8:42
  Speaker 3: We're probably the largest manufacturer of mesenchymal stem cells in
• 8:46
  Speaker 3: the world. We have an incredible lab, great scientists that
• 8:52
  Speaker 3: are working on you know, our current products, but also
• 8:54
  Speaker 3: the next generation stem cell products. We were the official
• 8:59
  Speaker 3: stem cell provider of the UFC. We've treated a lot
• 9:03
  Speaker 3: of NFL, NBA, you know, pretty much any professional sports league.
• 9:08
  Speaker 3: We've had somebody from their league come to us. And
• 9:12
  Speaker 3: you know, we focus on muscular skeletal so like shoulders, knees,
• 9:15
  Speaker 3: hernied to disc we're probably best at hernia disc So
• 9:20
  Speaker 3: we have a paper that we're should be publishing here
• 9:23
  Speaker 3: in the next two months.
• 9:24
  Speaker 4: Over five hundred patients.
• 9:25
  Speaker 3: I think there's going to be well over eighty percent
• 9:29
  Speaker 3: success rate in those hernia to disc procedures, So that's
• 9:34
  Speaker 3: really a focus for CPI. And of course we do
• 9:38
  Speaker 3: a five day say you went for for a week long,
• 9:41
  Speaker 3: so it's very structured. We're conditioning the body to potentially
• 9:45
  Speaker 3: respond better to the stem cells, do a lot of
• 9:48
  Speaker 3: hyperbaric oxygen in a D plus pulse, selectro man Field therapy,
• 9:53
  Speaker 3: et cetera. Uh, just getting the body ready for those
• 9:56
  Speaker 3: those stem cells. And then we have TAM Center, which
• 10:00
  Speaker 3: you know, the focus is cancer, but we'll also be
• 10:02
  Speaker 3: doing some other autoimmune diseases and those type of things.
• 10:06
  Speaker 3: But our chief scientific Officer, for instance, is Franco Marion Cola.
• 10:11
  Speaker 3: He was the former chief of Infectious Disease and Iminogenetics
• 10:14
  Speaker 3: for the National and Suits of Health in the US.
• 10:17
  Speaker 3: He co authored the main textbook that oncologists use for
• 10:21
  Speaker 3: immunotherapy for cancer. He's the founder and editor in chief
• 10:25
  Speaker 3: of the Journal of Translational Medicine, so he's just kind
• 10:29
  Speaker 3: of a giant in the cancer immunotherapy field. And then
• 10:32
  Speaker 3: we have our Chief of Innovation is Ali Asadi. Doctor
• 10:37
  Speaker 3: Asadi was the chief of Innovation for Illumina, which is
• 10:41
  Speaker 3: the largest sequencing company based out of San Diego. He
• 10:45
  Speaker 3: actually is a co inventor on the chips that go
• 10:48
  Speaker 3: into the sequencers, and he's invented a number of other
• 10:52
  Speaker 3: really revolutionary technologies, the somal logic, ten thousand protein, next
• 10:57
  Speaker 3: generation sequencing chemistry, and yeah, many other things. So we
• 11:03
  Speaker 3: have about twenty about twenty PhDs right now. Uh, you know,
• 11:07
  Speaker 3: ranging from you know, Harvard, yel Mi, t uh, you know,
• 11:11
  Speaker 3: top scientists working on this mission, which is to help people.
• 12:13
  Speaker 1: Well, that mission is far more complicated when you're dealing
• 12:19
  Speaker 1: with diseases like cancer and autoimmune.
• 12:22
  Speaker 2: And so forth.
• 12:22
  Speaker 1: So if you were to just take the last ten
• 12:27
  Speaker 1: years and bring them up to the current, what would
• 12:30
  Speaker 1: you say has been the greatest challenge that you face
• 12:34
  Speaker 1: in creating what you have today?
• 12:37
  Speaker 3: Well, I mean, gosh, it's been really hard. So we
• 12:42
  Speaker 3: opened August fifteenth, twenty fifteen, so it's almost eleven years,
• 12:47
  Speaker 3: and you know, it was really hard. I mean we're
• 12:50
  Speaker 3: in Tijuana, Mexico. We didn't speak the language.
• 12:55
  Speaker 4: You know, there's a.
• 12:55
  Speaker 3: Lot I love tj now, but you know, when you're
• 12:59
  Speaker 3: moving there and doing business there and you haven't done
• 13:03
  Speaker 3: that before. That can be a bit a lot of unknowns,
• 13:08
  Speaker 3: and so, you know, it was really just the perseverance
• 13:13
  Speaker 3: in the Yeah, there's a and I'm not saying this complaining,
• 13:17
  Speaker 3: but there was a lot of suffering over the last
• 13:20
  Speaker 3: you know, especially the first five or six years, where
• 13:23
  Speaker 3: we didn't see our families, We didn't see you know,
• 13:25
  Speaker 3: we were away from home. My home is in Nashville,
• 13:29
  Speaker 3: you know, Scottie Detrick and I we the first six
• 13:32
  Speaker 3: months we lived in the hospital because we wanted to
• 13:35
  Speaker 3: know everything we possibly could about the hospital. Then we
• 13:38
  Speaker 3: got a condo and house together. But we would wake
• 13:41
  Speaker 3: up drink coffee talking about work.
• 13:45
  Speaker 4: We'd go work all day long.
• 13:48
  Speaker 3: We'd come home probably seven or eight o'clock at night,
• 13:50
  Speaker 3: eating dinner, talking about the work. And we would do
• 13:55
  Speaker 3: it every single day, seven days a week for the
• 13:58
  Speaker 3: first five or six years. So, uh, you know, just
• 14:02
  Speaker 3: a there was a lot to overcome. Every day was
• 14:05
  Speaker 3: a new obstacle. So I wouldn't say it's any one thing.
• 14:07
  Speaker 3: It was more of like, ah, it was just kind
• 14:11
  Speaker 3: of a long line of stuff, right, So what would
• 14:16
  Speaker 3: what would you say has been your biggest success? Well,
• 14:21
  Speaker 3: I think the team that we've built, you know, kind
• 14:24
  Speaker 3: of speaks for itself, you know, getting that level of
• 14:26
  Speaker 3: those level of scientists where you know, ten years ago
• 14:31
  Speaker 3: we had trouble people even wanting to talk to us,
• 14:35
  Speaker 3: especially like the leading scientists, and now we have them
• 14:40
  Speaker 3: working with us, and we published in peer review, you know,
• 14:43
  Speaker 3: pretty much every month. I've been an author on two
• 14:47
  Speaker 3: papers this year. Uh, and so you know, I think
• 14:51
  Speaker 3: that really shows the success in where we're at as
• 14:54
  Speaker 3: an organization. I've seen a lot of different cases, uh,
• 14:59
  Speaker 3: for stem cells. You know, people with really bad her
• 15:03
  Speaker 3: needed discs that were you know, couldn't walk now can
• 15:06
  Speaker 3: walk with cancer. Although I don't like to suggest that
• 15:10
  Speaker 3: we have a cancer cure or anything like that, but
• 15:13
  Speaker 3: I've definitely seen metastatic patients have their cancer completely go away,
• 15:18
  Speaker 3: and that's always a blessing. So, you know, successes with patients,
• 15:22
  Speaker 3: we see them every week. You know, we have about
• 15:23
  Speaker 3: thirty five patients return every week. Patients come back at
• 15:29
  Speaker 3: month six and month month twelve, and you know, some
• 15:34
  Speaker 3: weeks it's thirty five out of thirty five. That's not
• 15:37
  Speaker 3: every week, but I mean it's it's pretty incredible. Even
• 15:40
  Speaker 3: if you're at thirty out of thirty five. That's pretty
• 15:42
  Speaker 3: durn good, especially considering the the condition some people are
• 15:47
  Speaker 3: in when they come to us. So we get to
• 15:49
  Speaker 3: see miracles every single week, and especially on the stem
• 15:53
  Speaker 3: cell side, that's really a blessing.
• 15:56
  Speaker 2: Well, you know, just a full disclosure to everyone.
• 16:00
  Speaker 1: Was so generous and invited me to come for a actual visit.
• 16:05
  Speaker 2: So I spent five days.
• 16:07
  Speaker 1: As he said, it's a five day program on the
• 16:09
  Speaker 1: stem cell side. But during that stay in October last year,
• 16:14
  Speaker 1: I also got, thanks to.
• 16:16
  Speaker 2: A a full tour of the hospital.
• 16:19
  Speaker 1: So I love this because I when he starts talking,
• 16:23
  Speaker 1: you know, I know exactly what he's saying because I
• 16:25
  Speaker 1: experienced the physically being there, and I can tell you
• 16:30
  Speaker 1: on the stem cell side, I think I was maybe
• 16:32
  Speaker 1: the only one of fifty people that were in my
• 16:35
  Speaker 1: or about fifty people maybe you just said thirty five,
• 16:38
  Speaker 1: So let's just say thirty five that were in the
• 16:41
  Speaker 1: group that I was in that didn't have an injury
• 16:45
  Speaker 1: that was being.
• 16:45
  Speaker 2: Injected with stem cells.
• 16:47
  Speaker 1: So I had an IV one hundred and was it
• 16:50
  Speaker 1: one hundred and twenty million stem cells?
• 16:53
  Speaker 2: Is that right in?
• 16:54
  Speaker 4: Yes? Somewhere or there?
• 16:56
  Speaker 2: Yeah, that's about right.
• 16:57
  Speaker 1: So so you know, I I have.
• 17:00
  Speaker 2: To say, I was in no pain. I had a
• 17:02
  Speaker 2: wonderful time, and.
• 17:03
  Speaker 1: You know, really enjoyed every moment of that experience, particularly
• 17:08
  Speaker 1: because they do so many other integrative things along with
• 17:11
  Speaker 1: the the you know, the big kahuna, which is the
• 17:15
  Speaker 1: stem cells of course, but there as he mentioned there,
• 17:19
  Speaker 1: the NAD which is an IV three hours long. I
• 17:23
  Speaker 1: think it was done twice, and that prepares the mitochondria
• 17:27
  Speaker 1: for the stem cells and you know, keeping them healthier
• 17:31
  Speaker 1: and more receptive to the treatment. And then you did
• 17:35
  Speaker 1: the the blood osmosis right where you took the blood
• 17:41
  Speaker 1: out and ozone.
• 17:44
  Speaker 2: I'm sorry, I said, I meant to say ozone. And
• 17:46
  Speaker 2: then you also did the.
• 17:50
  Speaker 1: Morpheus on people who wanted to do something a little
• 17:53
  Speaker 1: more cosmetic.
• 17:55
  Speaker 2: Uh.
• 17:55
  Speaker 1: And then of course they did a full MRI full body.
• 18:00
  Speaker 2: They did a.
• 18:03
  Speaker 1: Complete work up on your blood.
• 18:07
  Speaker 2: I mean, so this is not for the faint of heart.
• 18:10
  Speaker 1: I mean, these are people that are very serious about
• 18:13
  Speaker 1: looking at the whole body and then integrating the stem
• 18:16
  Speaker 1: cell treatments with what their findings are.
• 18:20
  Speaker 2: So it is very focused.
• 18:22
  Speaker 1: But the point I was going to make is that
• 18:24
  Speaker 1: the other thirty four people who had injections, and I
• 18:29
  Speaker 1: was telling ed this kind of you know, laughingly saying
• 18:32
  Speaker 1: that because we're on a WhatsApp chat. But for two
• 18:34
  Speaker 1: and a half months, all I heard on the What's
• 18:37
  Speaker 1: app was, Oh, why did I do this? I'm in
• 18:39
  Speaker 1: such pain. I don't know what I was thinking. And
• 18:43
  Speaker 1: you know, I don't know if this was.
• 18:45
  Speaker 2: A huge mistake, and et cetera, et cetera.
• 18:47
  Speaker 1: So all of a sudden, at about the three month period,
• 18:52
  Speaker 1: the whole tenor change and people said, this is like
• 18:55
  Speaker 1: a miracle.
• 18:56
  Speaker 2: This is the greatest thing that ever happened to me,
• 18:59
  Speaker 2: my life life back. And so anyway, I asked it,
• 19:03
  Speaker 2: you know, why is that? What is this magic that changes?
• 19:07
  Speaker 1: So why don't you tell us tell the audience that
• 19:10
  Speaker 1: I thought it was very interesting.
• 19:13
  Speaker 3: Yeah, we always tell us to tell everyone to give
• 19:15
  Speaker 3: it ninety days. And normally when you get injected, you know,
• 19:19
  Speaker 3: if you're getting a joint or discs, the first you
• 19:23
  Speaker 3: know two or three weeks, you're in a good amount
• 19:25
  Speaker 3: of pain. And you know, we tell people, depending on
• 19:30
  Speaker 3: the specific case, everybody's different, but to start physical therapy
• 19:33
  Speaker 3: at week three or four, and you know, really give
• 19:36
  Speaker 3: the body time to heal. This isn't like the stem
• 19:39
  Speaker 3: cells that you know, there's a difference. All stem cells
• 19:41
  Speaker 3: aren't created equally. You know, this is a lot different
• 19:45
  Speaker 3: what we do. Our viability is ninety eight percent, whereas
• 19:48
  Speaker 3: in the US you're lucky if you get seventy five
• 19:53
  Speaker 3: percent of the cellers live. They are hypoxic, which is
• 19:58
  Speaker 3: a big difference than growing cells in thermoxia. I find
• 20:02
  Speaker 3: it people are always talking about, oh, you know, the
• 20:04
  Speaker 3: cells don't differentiate in the body. You know, they die
• 20:07
  Speaker 3: right away. It's like, well, what stem cells are you
• 20:10
  Speaker 3: talking about? It you're talking about hypoxically grown stem cells.
• 20:12
  Speaker 3: We know hypoxic cells, uh, survive longer. We know that
• 20:17
  Speaker 3: they produce more growth factors. And then we also use
• 20:20
  Speaker 3: a li sate scaffolding, which is the same media that
• 20:28
  Speaker 3: the cells are grown in. We inject that in something
• 20:32
  Speaker 3: that will form a jelly and it holds the cells
• 20:35
  Speaker 3: right in place to the area that we're treating.
• 20:39
  Speaker 2: So is that is that called.
• 20:42
  Speaker 4: That's actually it's a human platelet li sate.
• 20:46
  Speaker 3: So like, this is another difference between how we grow
• 20:49
  Speaker 3: our cells and other people's. Uh, most if not all,
• 20:54
  Speaker 3: of the stem cell companies that are treating patients they're
• 20:59
  Speaker 3: using fetal bovine serum to grow the stem cells in
• 21:04
  Speaker 3: h We use hp L or human platelet listate, which
• 21:09
  Speaker 3: probably costs I don't know, five or ten times more
• 21:12
  Speaker 3: uh to use HPL, but it's much much better. I mean,
• 21:16
  Speaker 3: would you rather have a you know, cal cal serum
• 21:20
  Speaker 3: or human serum that you're growing the cells in and
• 21:24
  Speaker 3: so uh, But we actually make a three D cellular
• 21:28
  Speaker 3: matrix scaffolding system that when when injected, it holds the
• 21:34
  Speaker 3: stem cells in place with the human platelet LI state.
• 21:39
  Speaker 3: So it's uh, you know that the cells are in
• 21:43
  Speaker 3: an environment that they're they're used to, that they're used
• 21:45
  Speaker 3: to growing. And so when people say they don't differentiate
• 21:50
  Speaker 3: uh in the body, you know, it's it's it's I
• 21:52
  Speaker 3: find it interesting because I'm thinking, well, what are they
• 21:54
  Speaker 3: what are they using? And you know, the science has
• 21:58
  Speaker 3: not been settled on that. I don't even and really
• 22:00
  Speaker 3: like to argue those points. They say, well, it's a
• 22:02
  Speaker 3: signaling cell. I agree, you get a lot of great
• 22:04
  Speaker 3: signals in there, produces ex zomes and those type of
• 22:07
  Speaker 3: things as well. But how we grow our cells is
• 22:10
  Speaker 3: a lot different and it's not like regular stem cells
• 22:15
  Speaker 3: that you hear about.
• 22:16
  Speaker 1: So we know that stem cells can come from the
• 22:18
  Speaker 1: bone marrow, from adipose tissue, from the umbilical cord.
• 22:23
  Speaker 2: So where do your where's your donor stem cell?
• 22:27
  Speaker 3: Yeah, they are origin umbilical cord lining and we have
• 22:33
  Speaker 3: have it from unvaccinated an unvaccinated umbilical cord, and we're
• 22:39
  Speaker 3: able to make you know what kind of Well, we
• 22:42
  Speaker 3: have a patented process where we can probably do five
• 22:45
  Speaker 3: hundred thousand to a million patients past two or three.
• 22:50
  Speaker 3: You know a lot of the times when you're getting
• 22:51
  Speaker 3: stem cells from other places, they're just replicating over and
• 22:56
  Speaker 3: over again. So you might get past ten, past fifteen.
• 22:59
  Speaker 3: Well there's a lot more sons cells when you start
• 23:01
  Speaker 3: doing more passes. So all of ours are past two
• 23:04
  Speaker 3: or past three, uh stem cells. So they're yeah, they're
• 23:08
  Speaker 3: very very potent with high viability, viability being you know,
• 23:12
  Speaker 3: they're alive. We did a Wharton jelly study and you
• 23:15
  Speaker 3: know you can take Wharton jelly and uh take stem
• 23:19
  Speaker 3: cells from Wharton jelly, plate them, mountain grow them. But
• 23:22
  Speaker 3: the Wharton jelly products being sold in the United States
• 23:25
  Speaker 3: minimally manipulated. Wharton jelly is not a stem cell product.
• 23:30
  Speaker 3: So we did a study where we picked six of
• 23:33
  Speaker 3: the top Wharton jelly brands. We tested them to one
• 23:38
  Speaker 3: see if there were any stem cells. There's a very
• 23:41
  Speaker 3: very small amount, much less than one percent. Those eighty
• 23:45
  Speaker 3: two to one hundred percent were dead. So you know,
• 23:50
  Speaker 3: that's kind of the quality that you're getting right now
• 23:52
  Speaker 3: from a lot of places in the US. That doesn't
• 23:54
  Speaker 3: mean they're all like that, but I would say the
• 23:56
  Speaker 3: majority of the product out there currently is not so good.
• 24:01
  Speaker 1: So let's talk about exozones as it relates to stem cells.
• 24:06
  Speaker 1: How do you differentiate and how do you use the
• 24:10
  Speaker 1: exosomes now because they've become so much more prevalent with
• 24:15
  Speaker 1: the treatments that you're doing.
• 24:17
  Speaker 4: Yeah, so, I mean stem cells produce exosomes.
• 24:19
  Speaker 3: I believe it's like every stem cell produces like five
• 24:22
  Speaker 3: thousand exosomes.
• 24:24
  Speaker 4: So I mean you're getting.
• 24:28
  Speaker 3: A lot of exosomes with stem cell treatments. The reason
• 24:31
  Speaker 3: we've never come out with an exosome product is because
• 24:35
  Speaker 3: we're not able to compete with the numbers that people
• 24:38
  Speaker 3: are claiming. So they'll claim, oh, it's ten billion exosomes
• 24:42
  Speaker 3: or fifty billion exosomes. We have another study actually coming
• 24:45
  Speaker 3: out in the next probably ninety days where we're testing
• 24:48
  Speaker 3: the different exosone products, and I mean, we haven't found
• 24:51
  Speaker 3: anything that is what they say it is. So you
• 24:55
  Speaker 3: get a lot of particulates and stuff like that, but
• 24:58
  Speaker 3: we haven't been able to come out with the product
• 25:00
  Speaker 3: that would actually.
• 25:03
  Speaker 4: Have the numbers that they're saying.
• 25:04
  Speaker 3: And we're not willing to do something that we think
• 25:07
  Speaker 3: is unethical in suggesting that we have a product that
• 25:11
  Speaker 3: is not So I think exisomes are good. I think
• 25:14
  Speaker 3: that the numbers that people are claiming for the most
• 25:16
  Speaker 3: part isn't true. And skim cells produce exisomes, so those
• 25:25
  Speaker 3: are the signals that go out there.
• 25:28
  Speaker 4: Now we do have a product. This is separate.
• 25:32
  Speaker 3: But on the on the cancer side, where we've gone
• 25:36
  Speaker 3: through thousands of tumor cell lines in silico so you
• 25:39
  Speaker 3: computerize model and we've picked what's called the most immenogenic
• 25:45
  Speaker 3: tumor cell lines, so the ones that could be seen
• 25:48
  Speaker 3: the most by the immune system. We then brought the
• 25:51
  Speaker 3: top ten in into the lab to see which one
• 25:54
  Speaker 3: was actually the most imenogenic.
• 25:57
  Speaker 4: Tumor cell line.
• 25:58
  Speaker 3: We then did gene knockdowns in silicota see what caused
• 26:02
  Speaker 3: which gene knockdown caused the most imenogenic tumor cell death,
• 26:08
  Speaker 3: brought those and found which one specifically caused the most
• 26:12
  Speaker 3: imenogenic UH tumor cell death. Then we knocked We use
• 26:17
  Speaker 3: the most imenogenic UH cell death gen knockdown in the
• 26:21
  Speaker 3: most imogenic tumor cell line UH to create a super
• 26:24
  Speaker 3: imogenic UH tumor cell line, and we created a secret
• 26:27
  Speaker 3: tome from that as being an incredible UH adjuvant. And
• 26:32
  Speaker 3: then from there that same tumor cell line, we're taking
• 26:35
  Speaker 3: out the evs. We're not gonna call them exisomes. Uh, yeah,
• 26:38
  Speaker 3: exisomes in there, but we're taking out the the evs
• 26:42
  Speaker 3: and UH using that that that combination as a adjuvant.
• 26:49
  Speaker 4: And signaling protocol for cancer patients.
• 26:52
  Speaker 3: And we're using those with our gendrinic cell vaccines, We're
• 26:54
  Speaker 3: using those with our neoantigen peptide vaccines UH, and using
• 26:58
  Speaker 3: those in combination with a lot of different things that
• 27:00
  Speaker 3: we're doing.
• 27:01
  Speaker 1: So but so much of the literature or online, and
• 27:05
  Speaker 1: this is where it gets, you know, questionable, because it
• 27:07
  Speaker 1: is a lot of.
• 27:08
  Speaker 2: Information online, maybe not from PubMed.
• 27:11
  Speaker 1: But from certain influencers or doctors or whoever that is
• 27:16
  Speaker 1: you know, points of view. But they say that, you
• 27:20
  Speaker 1: know that using stem cells with cancer patients can be
• 27:24
  Speaker 1: very tricky because you can inject the stem cell.
• 27:27
  Speaker 2: And create more tumor growth.
• 27:28
  Speaker 1: What do you what's your feeling about that thesis and
• 27:33
  Speaker 1: how do you defy that?
• 27:36
  Speaker 3: Yeah, so you know, we don't use stem cells for
• 27:40
  Speaker 3: cancer patients, so it's not a cancer treatment.
• 27:44
  Speaker 4: Okay, we do screen out for those that have had cancer.
• 27:49
  Speaker 3: We have some uh you know, protocols where we won't
• 27:53
  Speaker 3: you know, give IV stem cells to people with cancer
• 27:55
  Speaker 3: and those type of things. We take it on a
• 27:57
  Speaker 3: case by case basis. If they have like a hearn
• 28:00
  Speaker 3: a disc and they had cancer a few years ago,
• 28:03
  Speaker 3: we might treat them, we might not. There's different variables
• 28:06
  Speaker 3: that the doctors you know, talk about with every unique case.
• 28:09
  Speaker 4: But I actually don't think that and this is just
• 28:12
  Speaker 4: an opinion. By the way.
• 28:13
  Speaker 3: There's literature that that suggests that it might, and there's
• 28:17
  Speaker 3: a literature that suggests that it has anti cancer effects.
• 28:20
  Speaker 3: But I mean, we've treated what over five thousand patients,
• 28:26
  Speaker 3: and you know, stem cells cause cancer or you know,
• 28:31
  Speaker 3: we would have an explosion of that, which we absolutely
• 28:33
  Speaker 3: do not. So I think that we would know more
• 28:37
  Speaker 3: than anybody.
• 28:39
  Speaker 1: And then when you go back to the exisones just
• 28:41
  Speaker 1: two D and three D the new EDGI.
• 28:44
  Speaker 2: Zones that people are saying on the cutting edge of
• 28:48
  Speaker 2: the three D.
• 28:48
  Speaker 1: Do you do you know the distinction of those two
• 28:52
  Speaker 1: that you can explain it to us or have you
• 28:54
  Speaker 1: been following that.
• 28:56
  Speaker 4: I have not been following following that. I don't know
• 28:59
  Speaker 4: what they're well, I.
• 29:01
  Speaker 1: Mean they're using ends zone so much in aesthetic medicine,
• 29:04
  Speaker 1: so you know, it's it. It's becoming very consumer driven
• 29:08
  Speaker 1: rather than medically driven, so as much.
• 29:10
  Speaker 2: I mean so, I guess.
• 29:12
  Speaker 1: Anything that's new and a little bit you know, more
• 29:15
  Speaker 1: unique is getting a lot of attention. But for example,
• 29:19
  Speaker 1: I did the Morpheus treatment with your wonderful staff. By
• 29:24
  Speaker 1: the way, this is the other thing I need to
• 29:26
  Speaker 1: tell everybody. The people at the tom CPI Center are
• 29:32
  Speaker 1: he mentioned You know the team, but you know, you
• 29:35
  Speaker 1: get to the team goes all the way down to
• 29:37
  Speaker 1: the most junior, the person sweeping the floor, and you know, honestly, everyone,
• 29:44
  Speaker 1: without exception, was the most personable, the most interested, the
• 29:51
  Speaker 1: most qualified. I just want to give you that feedback
• 29:55
  Speaker 1: because you don't find that in fact, In fact, the
• 29:58
  Speaker 1: last thing I would ever do in the.
• 29:59
  Speaker 2: United Stays is go to a hospital.
• 30:02
  Speaker 1: And the first thing I would do, if God forbid
• 30:05
  Speaker 1: ever had you know, the reason to do it, it would be.
• 30:08
  Speaker 2: To come to you.
• 30:09
  Speaker 1: So there's a huge difference. And also the cleanliness, I
• 30:14
  Speaker 1: mean so much of so many of the hospitals in
• 30:16
  Speaker 1: the US. You know, people come out with sepsis or
• 30:19
  Speaker 1: some kind of you know, issues of that are based
• 30:23
  Speaker 1: on the hospital's bacterial load. So I don't know how
• 30:29
  Speaker 1: you do it, ed, I mean, really to run both
• 30:32
  Speaker 1: a consumer driven business with the stem cells and then
• 30:36
  Speaker 1: the medically driven with the cancer, and then have a
• 30:40
  Speaker 1: staff they can be as competent on both sides.
• 30:45
  Speaker 2: It's it's really pretty pretty impressive.
• 30:48
  Speaker 4: Thank you. Yeah, you know our team, it really is
• 30:51
  Speaker 4: a great team.
• 30:53
  Speaker 3: We have about three hundred employees, maybe maybe a little
• 30:56
  Speaker 3: bit more now, but a lot of the people that
• 30:59
  Speaker 3: are that you see in Mexico had been with.
• 31:01
  Speaker 4: Us for a long time.
• 31:02
  Speaker 3: Yes, uh, and they understand, uh, what we expect, our
• 31:08
  Speaker 3: expectations on how patients are treated.
• 31:11
  Speaker 1: Uh.
• 31:12
  Speaker 3: You know, it's pretty easy if if we have to
• 31:14
  Speaker 3: discipline somebody, because it's as simple as you know, how
• 31:17
  Speaker 3: would you have treated your mom or dad?
• 31:18
  Speaker 4: Is this how you treat a family?
• 31:20
  Speaker 3: And you know, it's we expect everyone to treat the
• 31:25
  Speaker 3: patients like they would their family, and uh, it.
• 31:29
  Speaker 4: Makes things a lot easier because they understand what that
• 31:32
  Speaker 4: is and they do it.
• 31:33
  Speaker 3: You know, we don't have to have those conversations very
• 31:36
  Speaker 3: often because our staff is they're they're they're awesome, a
• 31:40
  Speaker 3: lot of really great people. They care about the patients,
• 31:43
  Speaker 3: they care about outcome. They know, you know, the patients.
• 31:47
  Speaker 3: You know, a lot of times they're suffering, they're looking
• 31:49
  Speaker 3: for help, and you've got to have compassion. And we
• 31:51
  Speaker 3: also focus on the mind. You know, we have to,
• 31:53
  Speaker 3: at least for our cancer patients. We have two full
• 31:55
  Speaker 3: time psychologists. And you know, I think love is a treatment, right,
• 32:02
  Speaker 3: I think I think the more you love people and
• 32:04
  Speaker 3: can love them up, the better they're going to respond.
• 32:09
  Speaker 3: And I know our staff and our entire team you know,
• 32:12
  Speaker 3: actually loves the patient.
• 32:14
  Speaker 4: So that's that's when it come to us.
• 32:17
  Speaker 1: Yeah, and everybody was was so collaborative, that's you know,
• 32:22
  Speaker 1: I mean so many of the patients were in pain
• 32:26
  Speaker 1: and the group, you know, as they mentioned so because
• 32:30
  Speaker 1: they had had the shots directly into their injury. So
• 32:34
  Speaker 1: you know, they would come into them starting to talk
• 32:36
  Speaker 1: about the Morpheus because that's kind of a little bit lighter,
• 32:40
  Speaker 1: uh treatment than the other, the other modality. So you know,
• 32:44
  Speaker 1: the Morpheus, if nobody knows, if people don't do.
• 32:47
  Speaker 2: Not know, what it is, is a.
• 32:49
  Speaker 1: It's a radio frequency treatment right that gets into the dermis,
• 32:54
  Speaker 1: and but it's very.
• 32:55
  Speaker 2: Tricky because if it isn't done right, it can cause
• 32:58
  Speaker 2: loss of volume. What you're actually.
• 33:01
  Speaker 1: Trying to do is create more volume in an aging
• 33:05
  Speaker 1: face and also of course open a channel for the
• 33:09
  Speaker 1: stem cells to be received at the dermis, not just
• 33:13
  Speaker 1: sit on the surface of the epidermist. I hope that's
• 33:17
  Speaker 1: a reasonable explanation to someone.
• 33:21
  Speaker 2: Thank you well.
• 33:22
  Speaker 1: But so you know, the reality was that a lot
• 33:25
  Speaker 1: of those patients going into that room were in really
• 33:28
  Speaker 1: serious pain, and so now they add to that pain
• 33:32
  Speaker 1: the you know, the treatment, which you do.
• 33:35
  Speaker 2: Have to have a little numbing, and you know, it's
• 33:38
  Speaker 2: just some people. I have a high pain threshold. I
• 33:40
  Speaker 2: could have done it.
• 33:42
  Speaker 1: I know they would laugh at me if I had
• 33:43
  Speaker 1: told them this, But I could have done it without the.
• 33:47
  Speaker 2: Light ocane. But that's because I did it once.
• 33:50
  Speaker 1: Before, and I know they told me I was from
• 33:53
  Speaker 1: another planet because I could take it. But it saved
• 33:56
  Speaker 1: about forty five minutes off the time in the treatment.
• 34:00
  Speaker 1: But I wouldn't do it again that way because I
• 34:02
  Speaker 1: know it's much safer to do it with a numbing
• 34:05
  Speaker 1: But the point is that people are already in pain.
• 34:08
  Speaker 2: Now they come in and have more pain, so now
• 34:10
  Speaker 2: their whole body is in pain.
• 34:12
  Speaker 1: Plus they look awful because you've got all these little
• 34:15
  Speaker 1: red marks, you know, the little needle marks.
• 34:19
  Speaker 2: From the micro needling. That is what morpheus really is.
• 34:22
  Speaker 1: So anyway, I just thought i'd mentioned that because anybody
• 34:25
  Speaker 1: that's coming to do the stem cell side is going
• 34:30
  Speaker 1: to be offered that opportunity, and they all And you
• 34:33
  Speaker 1: also offer PEMF, which you know is another modality that
• 34:38
  Speaker 1: a lot of people had never have never experienced. Why
• 34:41
  Speaker 1: don't you tell us just quickly about that that protocol.
• 34:46
  Speaker 3: Yeah, I mean so, I'm a huge PEMF fan. Uh,
• 34:49
  Speaker 3: there's a lot of studies on it. It's great for
• 34:52
  Speaker 3: nerve pain, it's great for pain management. Uh, it increases
• 34:56
  Speaker 3: the amount of stem cells in the body. Their studies
• 34:58
  Speaker 3: that show that as well.
• 35:00
  Speaker 4: But we've we've got it.
• 35:01
  Speaker 3: We brought it in and people can read all the studies,
• 35:04
  Speaker 3: but we brought it in for pain, uh management. So
• 35:07
  Speaker 3: initially had it for our cancer patients, and it wouldn't
• 35:10
  Speaker 3: work for everyone, but you know, for most people, they
• 35:13
  Speaker 3: would get significant relief. And the cancer patients, you know,
• 35:17
  Speaker 3: when we started, they were staying with us for three.
• 35:19
  Speaker 4: Weeks at a time, so I mean we it was
• 35:22
  Speaker 4: kind of like a boot camp for them. They were
• 35:25
  Speaker 4: you know, in a lot of them.
• 35:26
  Speaker 3: We had an inpatient program an outpatient program, so we
• 35:29
  Speaker 3: have you know, twenty to twenty five patients staying in
• 35:32
  Speaker 3: the hospital with their loved one and then you know
• 35:35
  Speaker 3: their twenty five thirty patients outpatient and you want to
• 35:38
  Speaker 3: get their pain under control. We would also focus on
• 35:42
  Speaker 3: you know, their gut. So a lot of times cancer
• 35:44
  Speaker 3: patients are having to take opiates because they're in so
• 35:47
  Speaker 3: much pain. And the problem with the opiates if they're
• 35:51
  Speaker 3: in so much pain as it clogs up their their gut.
• 35:54
  Speaker 4: You know, it is a patient.
• 35:56
  Speaker 3: And so we would manage, uh do our best manage
• 36:00
  Speaker 3: a lot of the pain with coffee enemas so I
• 36:04
  Speaker 3: can drastically reduce pain, you know, and also cleaning out
• 36:09
  Speaker 3: the guts. So uh, you know, we would use those
• 36:12
  Speaker 3: combination uh PMF coffee enemas.
• 36:16
  Speaker 4: Uh, it's kind of like a.
• 36:17
  Speaker 3: Combination to really manage the pain of cancer patients. So
• 36:20
  Speaker 3: for stim cell patients, it's like a no brainer. You
• 36:23
  Speaker 3: know that they're there a bunch of pmfs, you know,
• 36:26
  Speaker 3: and anybody can can use them at any time.
• 36:29
  Speaker 1: Yeah, because you're sitting there in a chair and getting
• 36:32
  Speaker 1: an IV, let's say, you're kind of a captive audience.
• 36:35
  Speaker 3: And well, I think it was a little a lot
• 36:37
  Speaker 3: different when we first started for the first you know,
• 36:39
  Speaker 3: probably seven years until we started the renovation.
• 36:41
  Speaker 4: Of the hospital.
• 36:42
  Speaker 3: So you know, we used to get mostly you know,
• 36:46
  Speaker 3: in stage failed standard of care, uh with with not
• 36:50
  Speaker 3: a lot of options, and uh, we were really good
• 36:54
  Speaker 3: at extending life and increasing quality of life, you know.
• 36:58
  Speaker 4: So that's what I mean. We are really good at that.
• 37:02
  Speaker 3: Now since the renovation happened, we closed our cancer program
• 37:06
  Speaker 3: for about.
• 37:06
  Speaker 4: Two years as we were going through the renovation.
• 37:09
  Speaker 3: And the reason for that was so the checkpoint inhibitors
• 37:14
  Speaker 3: won the Nobel Prize or the inventors or the discoverers
• 37:17
  Speaker 3: of it won the Nobel Prize in twenty eighteen, that's
• 37:21
  Speaker 3: when the immune therapies for cancer got really popular in
• 37:24
  Speaker 3: the United States, and he started seeing their drastic increase
• 37:27
  Speaker 3: in survival with melanoma and lung cancer, which was awesome. Finally,
• 37:31
  Speaker 3: you know, for fifty years you didn't really see much
• 37:33
  Speaker 3: of a bump and then because it was just chemo
• 37:35
  Speaker 3: radiation surgery. But when the checkpoint inhibitors got popular, on
• 37:40
  Speaker 3: college has started using them more and more. And so
• 37:44
  Speaker 3: after about twenty eighteen that we started seeing a drop
• 37:46
  Speaker 3: in our response rate, you know, because we were doing
• 37:50
  Speaker 3: immunotherapy and by the time patients came to us, they
• 37:56
  Speaker 3: had actually already tried those immunotherapies and so they were
• 37:59
  Speaker 3: kind of resistant or the immune system wasn't responding well.
• 38:03
  Speaker 3: Before that, we would get patients that had never done
• 38:06
  Speaker 3: any immune therapy because it wasn't really available, and we
• 38:09
  Speaker 3: would see some amazing, you know results. I mean, we'd
• 38:12
  Speaker 3: see some patients, you know, stage four sent home to
• 38:17
  Speaker 3: die type patients that we were able to completely turn around. So,
• 38:21
  Speaker 3: but the response rates started dropping after twenty eighteen. So
• 38:25
  Speaker 3: the vision of TAM Center, the new TAM Center that
• 38:28
  Speaker 3: we have is to you know, checkpoint Hitter is kind
• 38:32
  Speaker 3: of caught up to where we were, and then we
• 38:36
  Speaker 3: wanted to do something that was next level.
• 38:38
  Speaker 4: So our new lab.
• 38:40
  Speaker 3: If someone is just diagnosed with cancer, I would say
• 38:44
  Speaker 3: we're the best place in the world to go to,
• 38:46
  Speaker 3: not necessarily.
• 38:47
  Speaker 4: For treatments, but for diagnostics. So you come to us.
• 38:51
  Speaker 3: We do a biops that we have in house pathologists,
• 38:54
  Speaker 3: in house digital pathology. We do all of the sequencing
• 38:58
  Speaker 3: on the tumor you know, tumor panel. The US might
• 39:00
  Speaker 3: have three hundred genes. You're if you're lucky. I think
• 39:03
  Speaker 3: the foundation one is the most popular when it's like
• 39:07
  Speaker 3: three hundred and thirty three and forty genes. We do
• 39:10
  Speaker 3: whole xome sequencing, which is like twenty thousand genes. We
• 39:14
  Speaker 3: also do you know, RNA sequencing, which is the expression
• 39:18
  Speaker 3: of the gene HLA typing. We take the whole xome sequencing,
• 39:21
  Speaker 3: RNA sequencing, and HLA typing and send it to our
• 39:25
  Speaker 3: bionformatics team and they make a prediction of the top
• 39:29
  Speaker 3: twenty new antigens, which are antigens that are on.
• 39:31
  Speaker 4: The tumor but not on healthy cells. And so we
• 39:35
  Speaker 4: have a person with those.
• 39:36
  Speaker 3: Top twenty r and then we make customized peptides for
• 39:41
  Speaker 3: those patients. Now, this is an a curative type treatment,
• 39:44
  Speaker 3: but this can be used in combination with standard of
• 39:47
  Speaker 3: care or anything else that they're doing.
• 39:50
  Speaker 4: It can very.
• 39:51
  Speaker 3: Much likely make the checkpoint hibit or immunite therapy is better.
• 39:55
  Speaker 3: It could slow down or prevent recurrence. That's what we're
• 40:00
  Speaker 3: using it for. But you get all of this information.
• 40:03
  Speaker 3: We also then do the Avenio test with it, which
• 40:06
  Speaker 3: is the Foundation one test. It's called Foundation one of
• 40:09
  Speaker 3: the US. We're the referral lab in all of Latin
• 40:12
  Speaker 3: America for roche for that test, so we think that
• 40:14
  Speaker 3: test for you too. About three hundred and thirty genes.
• 40:18
  Speaker 3: We do proteomics of the proteins. We have proteo panels,
• 40:23
  Speaker 3: so you're gonna get proteomics, digital pathology, and we combine.
• 40:30
  Speaker 3: We use a multiamic approach combining the different omics to
• 40:33
  Speaker 3: try to learn as much as we possibly can about
• 40:36
  Speaker 3: the patient's cancer. We give a list of clinical trials
• 40:39
  Speaker 3: that are available.
• 40:41
  Speaker 4: In the US.
• 40:42
  Speaker 3: We give on and off label recommendations. On label meaning
• 40:47
  Speaker 3: it was FDA approved for their specific cancer, off label
• 40:51
  Speaker 3: meaning it was approved for another cancer but still potentially work.
• 40:56
  Speaker 3: And then you know, we partner with the patient and
• 40:58
  Speaker 3: giving them as much information as we can and showing
• 41:02
  Speaker 3: them their different options. You know what we can offer
• 41:05
  Speaker 3: that others can. Is this the highest level of diagnostics?
• 41:08
  Speaker 4: Number one? As I was just just mentioning.
• 41:12
  Speaker 3: We also have treatments that our scientists have invented basically
• 41:17
  Speaker 3: that can be used with standard of care or can
• 41:22
  Speaker 3: be used by itself too.
• 41:26
  Speaker 4: We recommend really working.
• 41:27
  Speaker 3: With the patients and collogists at home too if they're
• 41:31
  Speaker 3: open to it, and doing kind of a joint treatment plan.
• 41:36
  Speaker 3: So we're also able to offer a dingdritic cell vaccine.
• 41:43
  Speaker 3: Dendritic cells are part of the innate immune system. On
• 41:46
  Speaker 3: the innate side, you have natural killer cells, macrophages and
• 41:51
  Speaker 3: gendritic cells. The adaptive side is the T cell and
• 41:55
  Speaker 3: the B cell. B cell produces anybody's The T cell
• 41:58
  Speaker 3: can have memory. You have a memory T cell, So
• 42:00
  Speaker 3: the dendritic cell passes the tumor antigen from the innate
• 42:04
  Speaker 3: side to the adaptive side to the memory side, and
• 42:07
  Speaker 3: hopefully you know you can if you can get a
• 42:09
  Speaker 3: T cell, a memory T cell doing the final killing
• 42:12
  Speaker 3: of the cancer, you might have a cure. So we
• 42:15
  Speaker 3: take a piece of the patient's tumor. We also take
• 42:18
  Speaker 3: out the patient's immune cells, separate out the deendritic cells,
• 42:21
  Speaker 3: liice the tumor, and excite those dendritic cells to the
• 42:26
  Speaker 3: patient's own tumor antigen and so, and then we inject
• 42:31
  Speaker 3: that into the limp node that the tumor is draining
• 42:36
  Speaker 3: into just to get the best immune response that we
• 42:40
  Speaker 3: possibly can. So that's something that you can't get in
• 42:43
  Speaker 3: the US as well. So the neo antigen peptide vaccine
• 42:49
  Speaker 3: and also the dendritic cell vaccine. We have a number
• 42:53
  Speaker 3: of new things going kind of like that the process
• 42:56
  Speaker 3: I told you about going through the thousands of tumor
• 42:58
  Speaker 3: cell lines and finding the most of enogenic. We have
• 42:59
  Speaker 3: an secret tome adjuvant coming out, and we have an
• 43:02
  Speaker 3: ev product coming out that's gonna be combined with that
• 43:05
  Speaker 3: DC and neely antigen vaccine as well. We don't like, uh,
• 43:09
  Speaker 3: we don't pre screen as far as if someone's a
• 43:11
  Speaker 3: drinker or not see them in those type of things.
• 43:13
  Speaker 3: We recommend to every patient. The doctors recommend, you know,
• 43:18
  Speaker 3: a very specific diet. We actually have a nutritionist that
• 43:20
  Speaker 3: sits down with the cancer patients and goes over different options,
• 43:24
  Speaker 3: but you know, uh, to address the gut microbiome, I mean,
• 43:28
  Speaker 3: coffee and emos is one. Uh, prebiotics, digestive enzymes, uh,
• 43:35
  Speaker 3: specific probiotics as well. Yes, and we'll make our own
• 43:38
  Speaker 3: key for in house as well for cancer patients.
• 43:42
  Speaker 4: Uh.
• 43:42
  Speaker 3: We haven't gotten into into this yet, but it is
• 43:45
  Speaker 3: definitely on the horizon for us. Is fecal transplants. You
• 43:50
  Speaker 3: need a reliable donor base uh of very healthy people,
• 43:54
  Speaker 3: and so we haven't felt uh, we just haven't had
• 43:57
  Speaker 3: the time to focus on that. There's gonna be a
• 43:59
  Speaker 3: lot of work to me can happen. But I am
• 44:01
  Speaker 3: a believer. I mean, the gut microbiome is very under explored.
• 44:07
  Speaker 3: Franco Ameroncola, AR Chief Scientific Officer. He was the first
• 44:10
  Speaker 3: scientist to publish on the gut microbiome in cancer, so
• 44:14
  Speaker 3: it's pure viewed, you know, paper on it. I forget
• 44:17
  Speaker 3: the year, but my understanding was he was the first,
• 44:19
  Speaker 3: so we all know it's a big thing. I mean,
• 44:21
  Speaker 3: there's studies that show that the mice that were eating
• 44:23
  Speaker 3: the feces of other mice had as strong of a
• 44:28
  Speaker 3: response to their cancer as using a checkpoint hibit or amunotherapy.
• 44:32
  Speaker 3: So I mean, I think about, as we're talking about it,
• 44:36
  Speaker 3: what could have the biggest impact on all cancer patients,
• 44:39
  Speaker 3: not necessarily coming to us, just in general, is if
• 44:43
  Speaker 3: we focused.
• 44:43
  Speaker 4: On their gut.
• 44:44
  Speaker 3: So I mean, I think, you know, our model in
• 44:46
  Speaker 3: Mexico was built to really translate science fast. So, as
• 44:53
  Speaker 3: I mentioned earlier, the problem with the FDA process, you know,
• 44:57
  Speaker 3: to get a drug to phase one, which is safety
• 44:59
  Speaker 3: as five seven years, thirty to fifty million dollars, and
• 45:03
  Speaker 3: you have these animal models, and animal models are way outdated.
• 45:05
  Speaker 3: We don't need animal models for the most part. Now
• 45:07
  Speaker 3: maybe it can be good for the most part. We
• 45:10
  Speaker 3: don't need these mice experiments we can make in silico predictions.
• 45:14
  Speaker 3: It's like we're doing mice experiments in the nineteen sixty
• 45:19
  Speaker 3: three when the FDA was formed, So it's like we've
• 45:21
  Speaker 3: moved way past that. I don't personally like animal experiments
• 45:26
  Speaker 3: on dogs and monkeys. I don't feel great about that.
• 45:29
  Speaker 3: That's a personal belief. But I think we don't need
• 45:33
  Speaker 3: to do all that. But we can go from discovery
• 45:37
  Speaker 3: to patient in six to twelve months and translate really fast.
• 45:40
  Speaker 3: And our goal is to be able to take our
• 45:41
  Speaker 3: data run at our hospital under a clinical trial model
• 45:47
  Speaker 3: and give it to the FDA and hopefully be able
• 45:49
  Speaker 3: to skip that phase one showing that we're already in humans,
• 45:52
  Speaker 3: we treated let's say twenty patients. Look it's safe, there's
• 45:55
  Speaker 3: actually some signs of efficacy here too, and have them
• 45:59
  Speaker 3: allow us to go to phase two or do a
• 46:01
  Speaker 3: two slash three and then you can roll into a
• 46:03
  Speaker 3: phase three. So I think that will have a big impact,
• 46:08
  Speaker 3: as this administration has actually done a good job. They're
• 46:12
  Speaker 3: not they're trying to move away from animal models to
• 46:16
  Speaker 3: good We've been wanting that for a long time. They're
• 46:19
  Speaker 3: trying to speed up the process, but it's still not
• 46:21
  Speaker 3: going to be as fast as what we're doing currently
• 46:24
  Speaker 3: in Mexico, and so I think that'll be a big impact,
• 46:27
  Speaker 3: especially when you're able to go through you know, let's
• 46:30
  Speaker 3: say we have three products. Our goal is three new
• 46:32
  Speaker 3: products a year, therapeutics a year to come out with.
• 46:35
  Speaker 3: So in five years that would be fifteen you know,
• 46:38
  Speaker 3: so fifteen times fifty million, you know, that's what would
• 46:44
  Speaker 3: be what the cost would have that would have been
• 46:46
  Speaker 3: for that. So we're saving that translate, we have a
• 46:49
  Speaker 3: better chance of actually finding a cure to cancer with
• 46:53
  Speaker 3: that if you have a much better chance doing fifteen
• 46:55
  Speaker 3: than one, right, So I.
• 46:57
  Speaker 4: Think that's big impact.
• 46:59
  Speaker 3: I think that the telehealth service that we build out
• 47:03
  Speaker 3: is going to have a huge impact. Will be licensed
• 47:06
  Speaker 3: in forty nine states in the next twelve months. For
• 47:09
  Speaker 3: our compound pharmacy, we'll be able to give people access
• 47:13
  Speaker 3: to a lot of different medications and regenerative medicine type treatments.
• 47:19
  Speaker 3: So I think that's going to have a big impact.
• 47:21
  Speaker 3: And then I'd like to open I'd like to open
• 47:23
  Speaker 3: like an M. D Anderson style hospital in Nashville and
• 47:29
  Speaker 3: build out the best cancer center in the world. There's
• 47:32
  Speaker 3: two parts. Like the peptides that people get in the US,
• 47:35
  Speaker 3: if they come from a compound pharmacy, those are those
• 47:39
  Speaker 3: are good, so that's a high quality. The compound pharmacies
• 47:43
  Speaker 3: buy from a company that sells the API, so.
• 47:48
  Speaker 4: We will be an API.
• 47:49
  Speaker 3: Manufacturer, so we may actually making the peptides, so our
• 47:54
  Speaker 3: compound pharmacy will be selling the peptides that were allowed
• 47:58
  Speaker 3: to sell in the US, depending on what the laws
• 48:01
  Speaker 3: say at that time, but we will be an API
• 48:04
  Speaker 3: manufacturer for others. I'm not a peptide expert or anything.
• 48:09
  Speaker 3: I know, there's people that know a lot more about peptides. Me.
• 48:15
  Speaker 3: Whenever I saw where the peptides were going, I was like,
• 48:18
  Speaker 3: I'd rather be able to manufacture this stuff. And because
• 48:20
  Speaker 3: quality is you know, Michelle, that's like my big thing.
• 48:23
  Speaker 3: Like a lot of these places, the quality just across
• 48:26
  Speaker 3: the board isn't good stem cells, you know, supplements, and
• 48:31
  Speaker 3: so I would much rather be making it myself or
• 48:35
  Speaker 3: have our team than and knowing the quality of stem cells.
• 48:40
  Speaker 3: We have the highest quality stem cells that's out there.
• 48:44
  Speaker 3: I know that nobody is manufacturing with the viability of
• 48:49
  Speaker 3: cells that we are. Nobody's manufacturing numbers and viability, So
• 48:53
  Speaker 3: seven billion cells a week at you know, ninety eight
• 48:56
  Speaker 3: nine nine percent viabilities.
• 48:59
  Speaker 4: Pretty maze.
• 49:00
  Speaker 3: I would say that, uh, you know, if someone has
• 49:03
  Speaker 3: cancer or an autoimmune disease, that there there is hope.
• 49:12
  Speaker 3: We are working on some of the most advanced diagnostics
• 49:15
  Speaker 3: and treatments out there, and you know, the mind is
• 49:23
  Speaker 3: might be the most important aspect of somebody's treatment.
• 49:26
  Speaker 4: You've got to train your mind.
• 49:28
  Speaker 3: I give the analogy if I were training a fighter,
• 49:32
  Speaker 3: I said, I don't worry about your mind, don't even
• 49:34
  Speaker 3: worry about you know, visualizing winning. It doesn't matter if
• 49:37
  Speaker 3: you think, oh, if you think you can lose, that's perfect.
• 49:39
  Speaker 3: I would be the worst coach ever. But when patients
• 49:42
  Speaker 3: are in the fight of their life, it's not really
• 49:46
  Speaker 3: focused on So you've got to get your mind right.
• 49:48
  Speaker 3: You got to forgive those that you might be holding
• 49:52
  Speaker 3: on to anger or hate or whatever might.
• 49:55
  Speaker 4: Be holding you back. You've got to get there.
• 49:57
  Speaker 3: You've got you gotta let go of any of the
• 49:59
  Speaker 3: thing that are pulling you down, because guess what, it's
• 50:01
  Speaker 3: not important.
• 50:02
  Speaker 4: It's not like when you're on your deathbed.
• 50:05
  Speaker 3: I've been with a lot of people at the hospital
• 50:07
  Speaker 3: their last moments, you know, and the most important thing
• 50:10
  Speaker 3: is family and friends and you know, really having that connection.
• 50:14
  Speaker 3: It's not all the money that we make, or it's
• 50:16
  Speaker 3: not all the cars or the whatever.
• 50:18
  Speaker 4: That stuff doesn't matter.
• 50:19
  Speaker 3: So you're really getting your mind right and letting go
• 50:23
  Speaker 3: of anything that's holding you back. I think might be
• 50:26
  Speaker 3: the most important thing that someone can do going into
• 50:28
  Speaker 3: something like that. And you know, for TAM, you know,
• 50:33
  Speaker 3: we're trying to change the world. We're trying to change healthcare.
• 50:36
  Speaker 3: Translational and Advanced Medical Center is doing things that are
• 50:40
  Speaker 3: truly translational, where we're making discoveries in the lab. The
• 50:44
  Speaker 3: doctors work on the same floor as the scientists that
• 50:47
  Speaker 3: can make quick discoveries. We can take quick action, we
• 50:51
  Speaker 3: can find out as much as we possibly can about
• 50:53
  Speaker 3: a patient, and there's there's options for people. So I
• 50:57
  Speaker 3: would just say for patients, get your mind right. You
• 51:00
  Speaker 3: know that there's there's hope, there's people that care about you,
• 51:04
  Speaker 3: and uh, we're here to do really whatever we can
• 51:06
  Speaker 3: to support. Thank you so much for having me, Michelle
• 51:09
  Speaker 3: and I appreciate all the support you do.
• 51:12
  Speaker 4: It's very nice.